Erik Dvergsten
YOU?
Author Swipe
View article: Supplementary Table 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Supplementary Table 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Subset of study population showing only gastrointestinal and genitourinary cancer patients
View article: Figure 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Figure 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Percentage of patients in cohort 1 who experienced one or more events by ED diagnosis. Percentage (n) of patients who experienced ≥1 event are displayed for each cancer type. GU, genitourinary; Gyn, gynecologic; Heme, hematologic; H…
View article: Table 3 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Table 3 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Conditional logistic regression models
View article: Table 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Table 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
ED diagnoses: summary of cohort 1
View article: Table 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Table 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Baseline patient characteristics and demographics by occurrence of ED visits
View article: Figure 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Figure 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Patient selection flowchart.
View article: Figure 3 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Figure 3 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Comparison of patients with comorbidities between cohorts, percent (n). ORs with 95% CIs are displayed in black for statistically significant comorbidities. The dotted line corresponds to zero patients and an OR of 1. OR not in scal…
View article: Supplementary Table 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Supplementary Table 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Frequency of events by authorizing provider specialty
View article: Data from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Data from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
The Centers for Medicare & Medicaid Services Hospital Outpatient Quality Reporting Program’s OP-35 rule penalizes health systems that have a higher-than-expected rate of emergency department (ED) visits or inpatient admissions for 10 poten…
View article: Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
The Centers for Medicare & Medicaid Services Hospital Outpatient Quality Reporting Program’s OP-35 rule penalizes health systems that have a higher-than-expected rate of emergency department (ED) visits or inpatient admissions for 10 poten…
View article: EP13.07-07 Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others
EP13.07-07 Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others Open
View article: Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration
Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration Open
Taxanes are currently the most frequently used chemotherapeutic agents in cancer care, where real‐world use has focused on minimizing adverse events and standardizing the delivery. Myelosuppression is a well‐characterized, adverse pharmaco…